First-in-human Study of S-588210 (S-488210+S-488211)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

September 22, 2021

Study Completion Date

September 22, 2021

Conditions
Lung CancerHead and Neck CancerBladder CancerEsophageal CancerMesothelioma
Interventions
BIOLOGICAL

S-488210

S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).

BIOLOGICAL

S-488211

S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).

Trial Locations (1)

W1T 7HA

University College London Clinical Research Facility, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shionogi

INDUSTRY